Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
4.050
-0.220 (-5.15%)
At close: Aug 1, 2025, 4:00 PM
4.030
-0.020 (-0.49%)
After-hours: Aug 1, 2025, 4:45 PM EDT

Company Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.

The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus.

It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics.

Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences, Inc.
Kezar Life Sciences logo
CountryUnited States
Founded2015
IPO DateJun 21, 2018
IndustryBiotechnology
SectorHealthcare
Employees55
CEOChristopher Kirk

Contact Details

Address:
4000 Shoreline Court, Suite 300
South San Francisco, California 94080
United States
Phone650 822 5600
Websitekezarlifesciences.com

Stock Details

Ticker SymbolKZR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001645666
CUSIP Number49372L100
ISIN NumberUS49372L2097
Employer ID47-3366145
SIC Code2834

Key Executives

NamePosition
Dr. Christopher J. Kirk Ph.D.Co-Founder, Chief Executive Officer and Director
John Franklin FowlerCo-Founder and Director
Marc L. Belsky CPAChief Financial Officer and Secretary
Mark SchillerChief Operations Officer
Dr. Jack Taunton Ph.D.Co-Founder
Pattie ChiangPrincipal Accounting Officer, Senior Vice President and Corporate Controller
Gitanjali JainSenior Vice President of Investor Relations and External Affairs
Joe TedrickVice President of Human Resources
Dr. Neel K. Anand Ph.D.Senior Vice President of Research and Drug Discovery
Zung ToChief Development Officer

Latest SEC Filings

DateTypeTitle
Jun 23, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
Apr 25, 2025ARSFiling
Apr 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025DEF 14AOther definitive proxy statements
Apr 1, 20258-KCurrent Report
Mar 25, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 25, 202510-KAnnual Report
Mar 25, 20258-KCurrent Report